Navigation Links
New agent strikes at respiratory syncytial virus replication
Date:5/5/2008

GALVESTON, Texas University of Texas Medical Branch at Galveston researchers have achieved promising results with a potential new weapon against respiratory syncytial virus, the most common cause of infant hospitalization in the United States.

In an effort to find an effective antiviral therapy for RSV, the scientists tested two types of complex, custom-designed molecule to interfere with the genetic machinery that RSV uses to replicate, or copy itself, within cells. Both of the so-called morpholino oligomers, created by Oregon-based AVI BioPharma, penetrated cultured human airway cells easily and produced only minimal toxicity. One of the two, designated AUG-2, significantly reduced RSV replication in both cell culture and mouse experiments.

Viral replication is one of the major pathogenetic processes of RSV, and we badly need a specific antiviral therapy, said UTMB Dr. Roberto Garofalo, senior author of a paper on the study to be published in the June issue of Molecular Therapy and now available in the Advance Online Publication section of the journals website. That's what an agent like this morpholino could give us.

RSV infects almost all children by age two, but normally causes only a cold-like upper respiratory infection. In some babies, however, it spreads to the lungs, where the inflammation it generates causes coughing, wheezing and extreme difficulty in breathing, a life-threatening clinical syndrome known as bronchiolitis.

Recent research by Garofalo and other investigators suggests that two key factors drive RSV bronchiolitis: an inflammatory overreaction by the cells that line the airways of the lungs, and a failure to respond to RSV by T lymphocytes (also known as T cells), immune system cells that ordinarily act to control viral infections.

Because a dangerous inflammatory response occurs so soon after RSV begins replicating in the lungs, Garofalo said, antiviral therapy by itself is unlikely to be sufficient to treat severe RSV infection in infants. But it could be a critical part of a combination therapy that also included drugs to reduce RSV-induced lung inflammation and boost T-cell response.

The virus continues to replicate for days in the lungs of infected infants, and it induces inflammation as long as it replicates, Garofalo said. So stopping viral replication would be a very important part of any therapeutic strategy for RSV.


'/>"/>
Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
2. China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent
3. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
4. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
5. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
6. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
9. IUPUI scientists report first 3-D view of anti-cancer agent
10. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
11. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates Insurance & ... community enrichment program, has teamed up with Citizens Opposed to Domestic Abuse in support ... abuse. To support all those victimized by the fear of violence in their own ...
(Date:2/8/2016)... ... February 08, 2016 , ... T.E.N., ... that nominations will be accepted February 8, 2016 through May 8, 2016 ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:2/8/2016)... ... 2016 , ... Discover the Rocky Mountain region’s longest running and impressive garden ... Attendees also get to see the most incredible gardens and home improvement experts that ... the Colorado Convention Center - 700 14th St. Denver CO, is an exciting event ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... In a historic vote among its members this weekend, the Shinnecock Indian ... facility and dispensary on tribal land near Southampton . ... provider for patients in the state,s Medical Cannabis Program. --> ... patients in the state,s Medical Cannabis Program. --> Tribal ... pursue designation from the State of New York ...
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 ... chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company ... retinal disease, announced today agreements for the clinical supply ... manufacture material at multiple sites, including Slough (UK), Visp ... --> Retinal diseases, such as age-related ...
(Date:2/8/2016)... -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today announced that ... 31, 2015, the Company achieved revenue of $8,195,839, a 27% ... in fiscal 2015. --> --> ... 2016 was $2,068,635, or $.03 per share, up 265% from ... the Q2 of fiscal year 2015. Gross margin for the ...
Breaking Medicine Technology: